Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Phase 3positiveDivarasibPositive
AI Analysis
Summary
Genentech's Divarasib demonstrated superiority over approved KRAS G12C inhibitors in a Phase III head-to-head trial for non-small cell lung cancer treatment.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Divarasib showed superiority in head-to-head Phase III trial against approved KRAS G12C inhibitors
Importance:8/10
Sentiment:
0.75
KRAS G12C inhibitorlung cancerclinical trialhead-to-head comparisononcology
Related Companies
Read the original article
Published by yahoo_finance on July 2, 2026 5:10 AM